Comparative Pharmacology
Head-to-head clinical analysis: BROMDAY versus BROMFENAC SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMDAY versus BROMFENAC SODIUM.
BROMDAY vs BROMFENAC SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, thereby suppressing histamine-mediated allergic and vasodilatory responses.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever. Specifically, bromfenac is a potent inhibitor of COX-2.
1-2 drops in each affected eye every 4-6 hours as needed, not to exceed 4 doses per day.
One drop (0.1 mL) of 0.09% ophthalmic solution (bromfenac 0.9 mg/mL) instilled into the affected eye(s) twice daily beginning 24 hours before cataract surgery and continuing on the day of surgery and for 14 days postoperatively.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; clinical context: short half-life supports twice-daily dosing in ophthalmic use)
Renal excretion (approximately 70%) as unchanged drug and metabolites; biliary/fecal excretion accounts for the remainder.
Renal: ~80% (primarily as unchanged drug and glucuronide conjugate); Biliary/Fecal: ~20%
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID